和铂医药（上海）有限公司 Harbour BioMed
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Harbour BioMed Announces First Patient Dosing of Phase 1b/2a Study of Anti-FcRn Batoclimab for Treating Neuromyelitis Optica Spectrum Disorder 2020-04-21 17:00
Harbour BioMed and Chia Tai Tianqing Pharmaceutical Group Ltd. Announce Strategic Alliance to Discover, Develop and Commercialize Innovative Biologics 2019-05-06 10:49
1 2 3 4 5